SEOUL — MEDIPOST Co., Ltd., a leading South Korean regenerative medicine company, has announced a strategic multi-year licensing partnership with Japan-based Teikoku Seiyaku Co., Ltd., granting exclusive commercialization rights for its cartilage repair therapy CARTISTEM® in Japan. The agreement strengthens MEDIPOST’s footprint in one of the world’s most advanced medical markets while addressing Japan’s significant osteoarthritis burden.
As part of the arrangement, Teikoku Seiyaku will receive exclusive authority to market, distribute and promote CARTISTEM® across Japan, while MEDIPOST will continue supplying the drug substance and maintaining full manufacturing control. The deal brings MEDIPOST an upfront payment of US$8 million, additional short-term milestone funding worth US$10 million linked to regulatory progress and further undisclosed milestone-based rewards tied to product sales.
Teikoku Seiyaku plans to capitalise on its established orthopedic care network, encompassing major hospitals and specialist clinics, to ensure early market penetration. The company also intends to enhance its medical outreach workforce to support clinical education, awareness and treatment adoption.
Japan’s aging citizen population has resulted in rising osteoarthritis prevalence, particularly knee osteoarthritis, creating a pressing need for new therapeutic options. CARTISTEM® is poised to become an important solution, offering regenerative potential and more advanced intervention possibilities compared to conventional treatment pathways.
MEDIPOST stated that the collaboration combines technological science leadership with commercial strength, enabling a faster and more effective introduction of next-generation cell therapy into Japan’s healthcare system. The partnership underscores confidence in CARTISTEM® and highlights growing global recognition of stem cell-based therapies as viable mainstream medical solutions.